What this story covers

Chemed's 10-K amendment corrects equity data: 1.2M outstanding shares at $487 avg price, 435K available. CEO/CFO certifications updated. $8B market value, 14.6M shares stable. No risk changes. Chemed Corporation's Amendment No. 1 to its 2024 10-K filing, submitted April 1, 2025, primarily corrects the equity compensation plan table, updating available shares for future issuance to 435,455 from an understated figure. Outstanding awards total 1,235,051 shares with a weighted-average exercise price of $487.07, emphasizing performance-based vesting tied to EPS and TSR metrics to align incentives with hospice and plumbing operations. Executive certifications from CEO Kevin McNamara and CFO Michael D. Witzeman affirm disclosure controls' effectiveness, omitting internal control assessments as no financials are restated. The amendment is narrow, leaving MD&A, risks, and financial statements unchanged, and directs investors to the original February 28, 2025, report. Market details show $8.06 billion non-affiliate voting stock value as of June 30, 2024, with 14.6 million shares outstanding by February 2025. No risk factor updates, maintaining focus on regulatory and operational challenges. This ensures transparency in governance and stockholder matters without broader implications.

Story snapshot